Literature DB >> 23380220

A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis.

Emma L Beckett1, Richard L Stevens, Andrew G Jarnicki, Richard Y Kim, Irwan Hanish, Nicole G Hansbro, Andrew Deane, Simon Keely, Jay C Horvat, Ming Yang, Brian G Oliver, Nico van Rooijen, Mark D Inman, Roberto Adachi, Roy J Soberman, Sahar Hamadi, Peter A Wark, Paul S Foster, Philip M Hansbro.   

Abstract

BACKGROUND: Cigarette smoke-induced chronic obstructive pulmonary disease (COPD) is a life-threatening inflammatory disorder of the lung. The development of effective therapies for COPD has been hampered by the lack of an animal model that mimics the human disease in a short timeframe.
OBJECTIVES: We sought to create an early-onset mouse model of cigarette smoke-induced COPD that develops the hallmark features of the human condition in a short time-frame. We also sought to use this model to better understand pathogenesis and the roles of macrophages and mast cells (MCs) in patients with COPD.
METHODS: Tightly controlled amounts of cigarette smoke were delivered to the airways of mice, and the development of the pathologic features of COPD was assessed. The roles of macrophages and MC tryptase in pathogenesis were evaluated by using depletion and in vitro studies and MC protease 6-deficient mice.
RESULTS: After just 8 weeks of smoke exposure, wild-type mice had chronic inflammation, mucus hypersecretion, airway remodeling, emphysema, and reduced lung function. These characteristic features of COPD were glucocorticoid resistant and did not spontaneously resolve. Systemic effects on skeletal muscle and the heart and increased susceptibility to respiratory tract infections also were observed. Macrophages and tryptase-expressing MCs were required for the development of COPD. Recombinant MC tryptase induced proinflammatory responses from cultured macrophages.
CONCLUSION: A short-term mouse model of cigarette smoke-induced COPD was developed in which the characteristic features of the disease were induced more rapidly than in existing models. The model can be used to better understand COPD pathogenesis, and we show a requirement for macrophages and tryptase-expressing MCs.
Copyright © 2013 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23380220      PMCID: PMC4060894          DOI: 10.1016/j.jaci.2012.11.053

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  64 in total

1.  Early-life chlamydial lung infection enhances allergic airways disease through age-dependent differences in immunopathology.

Authors:  Jay C Horvat; Malcolm R Starkey; Richard Y Kim; Simon Phipps; Peter G Gibson; Kenneth W Beagley; Paul S Foster; Philip M Hansbro
Journal:  J Allergy Clin Immunol       Date:  2010-02-01       Impact factor: 10.793

2.  Cigarette smoke exposure attenuates cytokine production by mouse alveolar macrophages.

Authors:  Gordon J Gaschler; Caleb C J Zavitz; Carla M T Bauer; Marko Skrtic; Maria Lindahl; Clinton S Robbins; Biao Chen; Martin R Stämpfli
Journal:  Am J Respir Cell Mol Biol       Date:  2007-09-13       Impact factor: 6.914

Review 3.  Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network.

Authors:  Tobias Welte; Thomas Köhnlein
Journal:  Semin Respir Crit Care Med       Date:  2009-03-18       Impact factor: 3.119

4.  Mouse mast cell tryptase mMCP-6 is a critical link between adaptive and innate immunity in the chronic phase of Trichinella spiralis infection.

Authors:  Kichul Shin; Gerald F M Watts; Hans C Oettgen; Daniel S Friend; Alan D Pemberton; Michael F Gurish; David M Lee
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

Review 5.  Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease.

Authors:  Rosanne M Séguin; Nicolay Ferrari
Journal:  Expert Opin Investig Drugs       Date:  2009-10       Impact factor: 6.206

6.  Alterations in lung mast cell populations in patients with chronic obstructive pulmonary disease.

Authors:  Cecilia K Andersson; Michiko Mori; Leif Bjermer; Claes-Göran Löfdahl; Jonas S Erjefält
Journal:  Am J Respir Crit Care Med       Date:  2009-11-19       Impact factor: 21.405

Review 7.  Systemic manifestations and comorbidities of COPD.

Authors:  P J Barnes; B R Celli
Journal:  Eur Respir J       Date:  2009-05       Impact factor: 16.671

8.  Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes.

Authors:  Kichul Shin; Peter A Nigrovic; James Crish; Eric Boilard; H Patrick McNeil; Katherine S Larabee; Roberto Adachi; Michael F Gurish; Reuben Gobezie; Richard L Stevens; David M Lee
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

Review 9.  Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis.

Authors:  Sonal Singh; Aman V Amin; Yoon K Loke
Journal:  Arch Intern Med       Date:  2009-02-09

10.  Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases.

Authors:  Jeroen A J Vanoirbeek; Manuela Rinaldi; Vanessa De Vooght; Steven Haenen; Sonja Bobic; Ghislaine Gayan-Ramirez; Peter H M Hoet; Erik Verbeken; Marc Decramer; Benoit Nemery; Wim Janssens
Journal:  Am J Respir Cell Mol Biol       Date:  2009-04-03       Impact factor: 6.914

View more
  84 in total

1.  Mucosal production of uric acid by airway epithelial cells contributes to particulate matter-induced allergic sensitization.

Authors:  M J Gold; P R Hiebert; H Y Park; D Stefanowicz; A Le; M R Starkey; A Deane; A C Brown; G Liu; J C Horvat; Z A Ibrahim; M B Sukkar; P M Hansbro; C Carlsten; S VanEeden; D D Sin; K M McNagny; D A Knight; J A Hirota
Journal:  Mucosal Immunol       Date:  2015-10-28       Impact factor: 7.313

Review 2.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

3.  Fibulin-1 regulates the pathogenesis of tissue remodeling in respiratory diseases.

Authors:  Gang Liu; Marion A Cooley; Andrew G Jarnicki; Alan C-Y Hsu; Prema M Nair; Tatt Jhong Haw; Michael Fricker; Shaan L Gellatly; Richard Y Kim; Mark D Inman; Gavin Tjin; Peter A B Wark; Marjorie M Walker; Jay C Horvat; Brian G Oliver; W Scott Argraves; Darryl A Knight; Janette K Burgess; Philip M Hansbro
Journal:  JCI Insight       Date:  2016-06-16

4.  MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD.

Authors:  Alan C-Y Hsu; Kamal Dua; Malcolm R Starkey; Tatt-Jhong Haw; Prema M Nair; Kristy Nichol; Nathan Zammit; Shane T Grey; Katherine J Baines; Paul S Foster; Philip M Hansbro; Peter A Wark
Journal:  JCI Insight       Date:  2017-04-06

5.  The elevated CXCL5 levels in circulation are associated with lung function decline in COPD patients and cigarette smoking-induced mouse model of COPD.

Authors:  Jun Chen; Luqi Dai; Tao Wang; Junyun He; Yashu Wang; Fuqiang Wen
Journal:  Ann Med       Date:  2019-07-16       Impact factor: 4.709

Review 6.  Mast cell proteases as pharmacological targets.

Authors:  George H Caughey
Journal:  Eur J Pharmacol       Date:  2015-05-07       Impact factor: 4.432

7.  SAA drives proinflammatory heterotypic macrophage differentiation in the lung via CSF-1R-dependent signaling.

Authors:  Desiree Anthony; Jonathan L McQualter; Maria Bishara; Ee X Lim; Selcuk Yatmaz; Huei Jiunn Seow; Michelle Hansen; Michelle Thompson; John A Hamilton; Louis B Irving; Bruce D Levy; Ross Vlahos; Gary P Anderson; Steven Bozinovski
Journal:  FASEB J       Date:  2014-05-20       Impact factor: 5.191

8.  The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model.

Authors:  A G Jarnicki; H Schilter; G Liu; K Wheeldon; A-T Essilfie; J S Foot; T T Yow; W Jarolimek; P M Hansbro
Journal:  Br J Pharmacol       Date:  2016-10-12       Impact factor: 8.739

Review 9.  Development of mast cells and importance of their tryptase and chymase serine proteases in inflammation and wound healing.

Authors:  Jeffrey Douaiher; Julien Succar; Luca Lancerotto; Michael F Gurish; Dennis P Orgill; Matthew J Hamilton; Steven A Krilis; Richard L Stevens
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

Review 10.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.